NCT06465329 2026-02-12
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
18 trialsNCT06190951 2026-02-10
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT05208944 2026-01-20
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Recruiting
NCT06161441 2026-01-12
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT06848088 2026-01-12
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
Regeneron Pharmaceuticals
Phase 2 Enrolling by invitation
NCT04526899 2026-01-08
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
Phase 2 Completed
NCT04154943 2025-12-23
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Completed
NCT06769698 2025-12-16
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Not yet recruiting
NCT06463665 2025-09-26
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT03916627 2025-04-11
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT04291105 2025-03-26
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
Phase 2 Recruiting
NCT04050436 2025-01-27
CERPASS
Replimune Inc.
Phase 2 Active not recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT03669718 2023-12-29
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT03430063 2022-11-03
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT04373083 2021-01-15
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
Regeneron Pharmaceuticals
Phase 2 Withdrawn
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed